Effect of a Ceramide NP-Containing Moisturizer on Skin Barrier Function in Adults with Atopic Dermatitis: A Randomized, Double-Blind, Placebo-Controlled Study
- 1Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, China
Abstract
Introduction: Atopic dermatitis (AD) is a chronic inflammatory skin disease associated with epidermal barrier dysfunction. This study aimed to evaluate the effects of a ceramide NP-containing soothing and moisturizing emollient cream on skin barrier function in adult patients with AD.
Methods: In this single-center, randomized, double-blind, placebo-controlled parallel trial, 60 adults with moderate atopic dermatitis were randomly assigned (1:1) to receive standard therapy with either the soothing and moisturizing emollient cream or placebo. Skin barrier parameters and clinical outcomes were assessed on days 21 and 42.
Results: Both groups demonstrated overall improvements in skin barrier parameters, including stratum corneum hydration, transepidermal water loss, and casual sebum levels, with generally more favorable trends observed in the intervention group. However, between-group differences in changes from baseline did not reach statistical significance, and no significant between-group differences were observed in skin surface pH. All clinical outcomes, including EASI, SCORAD, DLQI, and VAS scores for pruritus and insomnia, improved significantly from baseline in both groups (p < 0.05), with numerically greater improvements generally observed in the intervention group and more pronounced improvements at day 42 than at day 21.
Conclusion: This study evaluated the incremental value of the emollient under real-world clinical conditions. The soothing and moisturizing emollient cream showed favorable trends in improving skin barrier parameters and clinical symptoms in adults with AD when used as an adjunct to standard therapy. Larger, rigorously designed studies are warranted to confirm its efficacy and long-term clinical value.
Related
- Effectiveness and Safety of a Moisturizer Containing Centella Asiatica Extract, Ceramide NP, and Panthenol for Erythema and Skin Barrier in Erythematotelangiectatic Rosacea: A Randomized Controlled Trial Study.
- Patient-Reported Outcomes With Episoft® AC SPF 50+, a Ceramide-Based Moisturizer, in Acne-Related Post-procedural Care: A Real-World Multicenter Observational Study From India (PROCEED Study).
- Effect of a lotion containing the heat-treated probiotic strain Lactobacillus johnsonii NCC 533 on Staphylococcus aureus colonization in atopic dermatitis
- Impact of Dupilumab Therapy on Skin Barrier Function in Patients With Moderate-to-Severe Atopic Dermatitis: A Phase IV, Non-Randomized, Open-Label, Parallel-Group Clinical Study.
- Does Baseline Severity of Atopic Dermatitis Impact the Long-Term Efficacy of Abrocitinib? Post-hoc Analysis of Two Randomized Trials
BibTeX
@article{gu2026effect,
title = {{Effect of a Ceramide NP-Containing Moisturizer on Skin Barrier Function in Adults with Atopic Dermatitis: A Randomized, Double-Blind, Placebo-Controlled Study}},
author = {Chao-ying Gu and Jia-yi Ying and Hui-bin Yin and Chun-yun Huang and Lei-hong Xiang},
journal = {Skin Pharmacology and Physiology},
year = {2026},
month = oct,
doi = {10.1159/spp/aetag011},
url = {https://doi.org/10.1159/spp/aetag011},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Effect of a Ceramide NP-Containing Moisturizer on Skin Barrier Function in Adults with Atopic Dermatitis: A Randomized, Double-Blind, Placebo-Controlled Study
AU - Chao-ying Gu
AU - Jia-yi Ying
AU - Hui-bin Yin
AU - Chun-yun Huang
AU - Lei-hong Xiang
PY - 2026
DA - 2026/10/13
JO - Skin Pharmacology and Physiology
DO - 10.1159/spp/aetag011
UR - https://doi.org/10.1159/spp/aetag011
AB - Introduction: Atopic dermatitis (AD) is a chronic inflammatory skin disease associated with epidermal barrier dysfunction. This study aimed to evaluate the effects of a ceramide NP-containing soothing and moisturizing emollient cream on skin barrier function in adult patients with AD. Methods: In this single-center, randomized, double-blind, placebo-controlled parallel trial, 60 adults with moderate atopic dermatitis were randomly assigned (1:1) to receive standard therapy with either the soothing and moisturizing emollient cream or placebo. Skin barrier parameters and clinical outcomes were assessed on days 21 and 42. Results: Both groups demonstrated overall improvements in skin barrier parameters, including stratum corneum hydration, transepidermal water loss, and casual sebum levels, with generally more favorable trends observed in the intervention group. However, between-group differences in changes from baseline did not reach statistical significance, and no significant between-group differences were observed in skin surface pH. All clinical outcomes, including EASI, SCORAD, DLQI, and VAS scores for pruritus and insomnia, improved significantly from baseline in both groups (p < 0.05), with numerically greater improvements generally observed in the intervention group and more pronounced improvements at day 42 than at day 21. Conclusion: This study evaluated the incremental value of the emollient under real-world clinical conditions. The soothing and moisturizing emollient cream showed favorable trends in improving skin barrier parameters and clinical symptoms in adults with AD when used as an adjunct to standard therapy. Larger, rigorously designed studies are warranted to confirm its efficacy and long-term clinical value.
SN - 1660-5527
SN - 1660-5535
ER -